Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VCAM1 | P19320 | 1/20 | 0.33 |
| ▸ | TTR | P02766 | 2/20 | 0.31 |
| ▸ | ALB | P02768 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | RAD51 | Q06609 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2097255 | 1.00 | VCAM1 (0.33) | VCAM1TTRALBMEN1KMT2A | |
| SCHEMBL6898133 | 0.73 | VCAM1 (0.40) | VCAM1TTRALBMEN1KMT2A | |
| SCHEMBL5250677 | 0.69 | VCAM1 (0.39) | VCAM1TTRALBMEN1KMT2A | |
| SCHEMBL2040623 | 0.66 | VCAM1 (0.41) | VCAM1TTRALBMEN1KMT2A | |
| SCHEMBL3048555 | 0.66 | VCAM1 (0.41) | VCAM1TTRALBMEN1KMT2A | |
| SCHEMBL3955231 | 0.64 | TTR (0.42) | VCAM1TTRALBMEN1KMT2A | |
| SCHEMBL21918828 | 0.64 | VCAM1 (0.39) | VCAM1TTRALBMEN1KMT2A | |
| SCHEMBL22130481 | 0.64 | TTR (0.48) | VCAM1TTRALBMEN1KMT2A | |
| SCHEMBL17546133 | 0.64 | TRPV4 (0.39) | VCAM1TTRALBMEN1KMT2A | |
| SCHEMBL11525607 | 0.64 | VCAM1 (0.39) | VCAM1TTRALBMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163753-B2 | 2-(4-(4-(4-chlorophenyl)oxazol-2-yl)phenoxymethyl)-2-methyl-6-nitro-2,3-dihydroimidazo[2,1-b]oxazole; bactericide; excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and atypical acid-fast bacteria | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2012-04-24 | — | — | US | disclosed |
| EP-1678185-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS | OTSUKA PHARMA CO LTD (JP) | 2008-10-08 | — | — | EP | disclosed |
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | OTSUKA PHAMACEUTICAL CO., LTD. (JP) | 2008-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080119478-A1 | 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis | NR2C2, NR0B2, NR4A2 | VCAM1 4046/4885TTR 4486/4885ALB 4118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.